Company intelligence / Profile preview

Arma Biosciences

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Arma Biosciences is developing a first-in-class, real-time mobile biomarker monitoring device for at-home and remote patient care. Their universal molecular-sensor platform enables comprehensive monitoring of biomarkers, pathogens, and metabolites in biological fluids such as blood, saliva, or urine. The initial focus is on remote management of chronic cardiovascular, renal, or metabolic conditions to prevent rehospitalizations and improve outcomes. No clinical trial results are available as the company focuses on diagnostic/device technology rather than therapeutics.

Therapeutic areas: NephrologyMetabolic DisordersCardiovascularInfectious Diseases
Modalities: DevicePlatform technology (molecular sensor platform)
Industry: Physiological Monitoring

Partnerships

Analog Devices (technology partnership)

Beyond the preview

Go deeper on Arma Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arma Biosciences.

Explore the full profile